Neoagarooligosaccharide protects against hepatic fibrosis via inhibition of tgf‐β/smad signaling pathway

Abstract

Hepatic fibrosis occurs when liver tissue becomes scarred from repetitive liver injury and inflammatory responses; it can progress to cirrhosis and eventually to hepatocellular carcinoma. Previously, we reported that neoagarooligosaccharides (NAOs), produced by the hydrolysis of agar by β‐agarases, have hepatoprotective effects against acetaminophen overdose‐induced acute liver injury. However, the effect of NAOs on chronic liver injury, including hepatic fibrosis, has not yet been elucidated. Therefore, we examined whether NAOs protect against fibrogenesis in vitro and in vivo. NAOs ameliorated PAI‐1, α‐SMA, CTGF and fibronectin protein expression and decreased mRNA levels of fibrogenic genes in TGF‐β‐treated LX‐2 cells. Furthermore, downstream of TGF‐β, the Smad signaling pathway was inhibited by NAOs in LX‐2 cells. Treatment with NAOs diminished the severity of hepatic injury, as evidenced by reduction in serum alanine aminotransferase and aspartate aminotransferase levels, in carbon tetrachloride (CCl4)‐induced liver fibrosis mouse models. Moreover, NAOs markedly blocked histopathological changes and collagen accumulation, as shown by H&E and Sirius red staining, respectively. Finally, NAOs antagonized the CCl4‐induced upregulation of the protein and mRNA levels of fibrogenic genes in the liver. In conclusion, our findings suggest that NAOs may be a promising candidate for the prevention and treatment of chronic liver injury via inhibition of the TGF‐β/Smad signaling pathway.